Sage's seizure disorder drug fails late-stage trial

[September 12, 2017] (Reuters) - Sage Therapeutics Inc said on Tuesday its drug to treat a life-threatening seizure disorder failed to meet the main goal of a late-stage trial.

The trial was testing Sage's drug, brexanolone, plus standard of care in patients with super-refractory status epilepticus (SRSE) whose seizures persisted despite earlier treatments, versus a placebo plus standard of care.

There are currently no FDA-approved treatments for SRSE, Sage said.

(Reporting by Divya Grover in Bengaluru; Editing by Maju Samuel)

[© 2017 Thomson Reuters. All rights reserved.]

Copyright 2017 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.